A Clinical Evaluation of Efficacy and Safety of AyuAsmo Capsules in Patients Suffering From Bronchial Asthma.

Welex Laboratories Pvt Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

研究概览

暂无简介。

•2.Patients with diagnosis of bronchial asthma, for a period of at least 6 months prior to screening visit.
•3.Patients not on continue use of inhalers bronchodilators.
•4.Percentage FEV1 more than 50% of prediction (predicted values) on screening visit.
•5.Subjects willing to give informed consent and ready to comply with the study protocol.

•1.Known cases of severe/chronic diseases those interfere with study.
•2.Known cases of active malignancy.
•3.Subjects giving history of significant cardiovascular event less than 12 weeks prior to screening.
•4.Known cases of chronic cardiac illnesses
•5.Subjects having known chronic, contagious infectious disease, such as active tuberculosis, Hepatitis B or C, or HIV.
•6.Subjects with uncontrolled diabetes and hypertension.
•7.Subjects using any other investigational drug within 1 month prior to recruitment in this study.
•8.Known hypersensitivity to any of the ingredients used in study drug.
•9.Pregnant and Lactating females.
•10.Subjects currently participating in any other clinical study.
•11.Any other condition due to which patients are deemed to be unsuitable by the investigator for reason(s) not specifically stated in the exclusion criteria.

发起方

Welex Laboratories Pvt Ltd